Table 3.

Predicted TNFSF4 haplotypes in systemic sclerosis (SSc), SSc subsets, and healthy controls. Numbers in boldface are significant values.

TNFSF4 Haplotypes	rs12039904	rs10912580	rs844648	rs1234317	rs2205960	Frequency in Comparator	Frequency in Patients	p	OR (95% CI)
SSc vs controls
1	C	A	G	C	G	0.53	0.51	0.037	1.10 (0.97–1.24)
2	C	A	A	C	G	0.18	0.19	0.22	0.93 (0.79–1.09)
3	T	G	A	T	T	0.19	0.21	0.048	0.89 (0.76–1.04)
lcSSc vs controls
1	C	A	G	C	G	0.53	0.50	0.0022	0.87 (0.76–1.00)
2	C	A	A	C	G	0.18	0.19	0.86	1.01 (0.84–1.22)
3	T	G	A	T	T	0.19	0.23	0.00046	1.21 (1.02–1.44)
dcSSc vs controls
1	C	A	G	C	G	0.53	0.53	1	1.00 (0.83–1.19)
2	C	A	A	C	G	0.18	0.20	0.03	1.13 (0.90–1.42)
3	T	G	A	T	T	0.19	0.19	0.42	0.95 (0.75–1.20)
lcSSc vs dcSSc
1	C	A	G	C	G	0.53	0.50	0.012	0.87 (0.72–1.06)
2	C	A	A	C	G	0.20	0.19	0.13	0.90 (0.70–1.15)
3	T	G	A	T	T	0.19	0.23	0.0004	1.27 (1.00–1.63)
ACA+ vs controls
1	C	A	G	C	G	0.53	0.47	5.53 × 10−7	0.80 (0.67–0.95)
2	C	A	A	C	G	0.18	0.18	1	1.00 (0.80–1.24)
3	T	G	A	T	T	0.19	0.24	7.71 × 10−7	1.31 (1.07–1.61)
ATA+ vs controls
1	C	A	G	C	G	0.53	0.53	0.88	1.00 (0.82–1.23)
2	C	A	A	C	G	0.19	0.18	0.50	1.04 (0.80–1.34)
3	T	G	A	T	T	0.19	0.19	0.29	0.95 (0.73–1.22)
ACA+ vs ATA+
1	C	A	G	C	G	0.47	0.53	0.0013	1.26 (1.00–1.59)
2	C	A	A	C	G	0.19	0.19	0.78	1.03 (0.76–1.39)
3	T	G	A	T	T	0.24	0.18	0.00011	0.72 (0.53–0.96)

dcSSc: diffuse cutaneous SSc; ATA+: antitopoisomerase I antibodies; lcSSc: limited cutaneous SSc; ACA+: anticentromere antibodies.